Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Non-Current Deffered Revenue: 2021

  • Amylyx Pharmaceuticals' Non-Current Deffered Revenue was N/A to $35,000 in Q4 2021 from the same period last year, while for Dec 2021 it was $35,000, marking a year-over-year change of. This contributed to the annual value of $35,000 for FY2021, which is N/A change from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported Non-Current Deffered Revenue of $35,000 as of Q4 2021.
  • Over the past 5 years, Amylyx Pharmaceuticals' Non-Current Deffered Revenue peaked at $35,000 during Q4 2021, and registered a low of $35,000 during Q4 2021.
  • In the last 1 years, Amylyx Pharmaceuticals' Non-Current Deffered Revenue had a median value of $35,000 in 2021 and averaged $35,000.